AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015
Aug 19, 2015
31580_dirs_2015-08-19_03d637b0-697c-4f69-8830-b1ce410a1d1e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-08-17
Reporting Person: Higgons John Duncan (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-08-17 | Common stock | M | 20000 | $0.3025 | Acquired | 151835 | Direct |
| 2015-08-17 | Common stock | S | 20000 | $92.24 | Disposed | 131835 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-08-17 | Stock option (right to buy) | $0.3025 | M | 20000 | Disposed | 2019-08-12 | Common stock (20000) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.54 to $93.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on June 13, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.